-+ 0.00%
-+ 0.00%
-+ 0.00%

AbbVie, DISCO Pharmaceuticals Team Up On AND-Gated Bispecific Solid Tumor Therapeutics Using DISCOtech Platform; Deal Carries $40M Upfront, Up To $2.5B Milestones

Benzinga·11/19/2026 07:38:13
Listen to the news
  • The collaboration leverages DISCO’s proprietary DISCOtech® surfaceome mapping platform and AND-gated bispecific discovery approach together with AbbVie’s global oncology research and development expertise to identify and potentially advance highly selective AND-gated bispecific therapeutics.
  • Upon successful completion of specified research activities by DISCO, AbbVie will have the option to exclusively license selected programs for further development.